Cost items in melanoma patients by clinical characteristics and time from diagnosis
BackgroundCosts related to the care of melanoma patients have been rising over the past few years due to increased disease incidence as well as the introduction of innovative treatments. The aim of this study is to analyse CMM cost items based on stage at diagnosis, together with other diagnostic an...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-11-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1234931/full |
| _version_ | 1827766734825717760 |
|---|---|
| author | Alessandra Buja Claudia Cozzolino Claudia Cozzolino Anna Zanovello Anna Zanovello Ruggero Geppini Andrea Miatton Manuel Zorzi Mariagiovanna Manfredi Emanuela Bovo Paolo Del Fiore Saveria Tropea Luigi dall’Olmo Luigi dall’Olmo Carlo Riccardo Rossi Simone Mocellin Simone Mocellin Marco Rastrelli Marco Rastrelli Massimo Rugge Massimo Rugge |
| author_facet | Alessandra Buja Claudia Cozzolino Claudia Cozzolino Anna Zanovello Anna Zanovello Ruggero Geppini Andrea Miatton Manuel Zorzi Mariagiovanna Manfredi Emanuela Bovo Paolo Del Fiore Saveria Tropea Luigi dall’Olmo Luigi dall’Olmo Carlo Riccardo Rossi Simone Mocellin Simone Mocellin Marco Rastrelli Marco Rastrelli Massimo Rugge Massimo Rugge |
| author_sort | Alessandra Buja |
| collection | DOAJ |
| description | BackgroundCosts related to the care of melanoma patients have been rising over the past few years due to increased disease incidence as well as the introduction of innovative treatments. The aim of this study is to analyse CMM cost items based on stage at diagnosis, together with other diagnostic and prognostic characteristics of the melanoma.MethodsAnalyses were performed on 2,647 incident cases of invasive CMM that were registered in 2015 and 2017 in the Veneto Cancer Registry (RTV). Direct melanoma-related costs per patient were calculated for each year ranging from 2 years before diagnosis to 4 years after, and were stratified by cost items such as outpatient services, inpatient drug prescriptions, hospital admissions, hospice admissions, and emergency room treatment. Average yearly costs per patient were compared according to available clinical-pathological characteristics. Lastly, log-linear multivariable analysis was performed to investigate potential cost drivers among these clinical-pathological characteristics.FindingsOverall, the average direct costs related to melanoma are highest in the first year after diagnosis (€2,903) and then decrease over time. Hospitalization costs are 8 to 16 times higher in the first year than in subsequent years, while the costs of outpatient services and inpatient drugs decrease gradually over time. When stratified by stage it is observed that the higher expenditure associated with more advanced stages of CMM is mainly due to inpatient drug use.ConclusionThe results of the present study show that grouping patients according to tumour characteristics can improve our understanding of the different cost items associated with cutaneous malignant melanoma. CMM patients experience higher costs in the first year after diagnosis due to higher hospitalization and outpatient services. Policy makers should consider overall and stage-specific annual costs when allocating resources for the management of CMM patients. |
| first_indexed | 2024-03-11T11:45:09Z |
| format | Article |
| id | doaj.art-fc96b31979d044c38bba7c5d93de8fcb |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-11T11:45:09Z |
| publishDate | 2023-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-fc96b31979d044c38bba7c5d93de8fcb2023-11-09T15:09:56ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-11-011310.3389/fonc.2023.12349311234931Cost items in melanoma patients by clinical characteristics and time from diagnosisAlessandra Buja0Claudia Cozzolino1Claudia Cozzolino2Anna Zanovello3Anna Zanovello4Ruggero Geppini5Andrea Miatton6Manuel Zorzi7Mariagiovanna Manfredi8Emanuela Bovo9Paolo Del Fiore10Saveria Tropea11Luigi dall’Olmo12Luigi dall’Olmo13Carlo Riccardo Rossi14Simone Mocellin15Simone Mocellin16Marco Rastrelli17Marco Rastrelli18Massimo Rugge19Massimo Rugge20Department of Cardiologic, Vascular and Thoracic Sciences, and Public Health, University of Padua, Padua, ItalyDepartment of Cardiologic, Vascular and Thoracic Sciences, and Public Health, University of Padua, Padua, ItalySoft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology (IOV), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua, ItalyDepartment of Cardiologic, Vascular and Thoracic Sciences, and Public Health, University of Padua, Padua, ItalySoft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology (IOV), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua, ItalyDepartment of Cardiologic, Vascular and Thoracic Sciences, and Public Health, University of Padua, Padua, ItalyDepartment of Cardiologic, Vascular and Thoracic Sciences, and Public Health, University of Padua, Padua, ItalyVeneto Tumor Registry, Azienda Zero, Padua, ItalyDepartment of Cardiologic, Vascular and Thoracic Sciences, and Public Health, University of Padua, Padua, ItalyVeneto Tumor Registry, Azienda Zero, Padua, ItalySoft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology (IOV), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua, ItalySoft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology (IOV), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua, ItalySoft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology (IOV), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua, ItalyDepartment of Surgery, Oncology and Gastroenterology (DISCOG), University of Padua, Padua, ItalyDepartment of Surgery, Oncology and Gastroenterology (DISCOG), University of Padua, Padua, ItalySoft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology (IOV), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua, ItalyDepartment of Surgery, Oncology and Gastroenterology (DISCOG), University of Padua, Padua, ItalySoft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology (IOV), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua, ItalyDepartment of Surgery, Oncology and Gastroenterology (DISCOG), University of Padua, Padua, ItalyVeneto Tumor Registry, Azienda Zero, Padua, ItalyPathology and Cytopathology Unit, Department of Medicine-DIMED, University of Padua, Padua, ItalyBackgroundCosts related to the care of melanoma patients have been rising over the past few years due to increased disease incidence as well as the introduction of innovative treatments. The aim of this study is to analyse CMM cost items based on stage at diagnosis, together with other diagnostic and prognostic characteristics of the melanoma.MethodsAnalyses were performed on 2,647 incident cases of invasive CMM that were registered in 2015 and 2017 in the Veneto Cancer Registry (RTV). Direct melanoma-related costs per patient were calculated for each year ranging from 2 years before diagnosis to 4 years after, and were stratified by cost items such as outpatient services, inpatient drug prescriptions, hospital admissions, hospice admissions, and emergency room treatment. Average yearly costs per patient were compared according to available clinical-pathological characteristics. Lastly, log-linear multivariable analysis was performed to investigate potential cost drivers among these clinical-pathological characteristics.FindingsOverall, the average direct costs related to melanoma are highest in the first year after diagnosis (€2,903) and then decrease over time. Hospitalization costs are 8 to 16 times higher in the first year than in subsequent years, while the costs of outpatient services and inpatient drugs decrease gradually over time. When stratified by stage it is observed that the higher expenditure associated with more advanced stages of CMM is mainly due to inpatient drug use.ConclusionThe results of the present study show that grouping patients according to tumour characteristics can improve our understanding of the different cost items associated with cutaneous malignant melanoma. CMM patients experience higher costs in the first year after diagnosis due to higher hospitalization and outpatient services. Policy makers should consider overall and stage-specific annual costs when allocating resources for the management of CMM patients.https://www.frontiersin.org/articles/10.3389/fonc.2023.1234931/fullmelanomadirect costsspecific costscost of illnesshealth economicshealthcare assessment |
| spellingShingle | Alessandra Buja Claudia Cozzolino Claudia Cozzolino Anna Zanovello Anna Zanovello Ruggero Geppini Andrea Miatton Manuel Zorzi Mariagiovanna Manfredi Emanuela Bovo Paolo Del Fiore Saveria Tropea Luigi dall’Olmo Luigi dall’Olmo Carlo Riccardo Rossi Simone Mocellin Simone Mocellin Marco Rastrelli Marco Rastrelli Massimo Rugge Massimo Rugge Cost items in melanoma patients by clinical characteristics and time from diagnosis Frontiers in Oncology melanoma direct costs specific costs cost of illness health economics healthcare assessment |
| title | Cost items in melanoma patients by clinical characteristics and time from diagnosis |
| title_full | Cost items in melanoma patients by clinical characteristics and time from diagnosis |
| title_fullStr | Cost items in melanoma patients by clinical characteristics and time from diagnosis |
| title_full_unstemmed | Cost items in melanoma patients by clinical characteristics and time from diagnosis |
| title_short | Cost items in melanoma patients by clinical characteristics and time from diagnosis |
| title_sort | cost items in melanoma patients by clinical characteristics and time from diagnosis |
| topic | melanoma direct costs specific costs cost of illness health economics healthcare assessment |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1234931/full |
| work_keys_str_mv | AT alessandrabuja costitemsinmelanomapatientsbyclinicalcharacteristicsandtimefromdiagnosis AT claudiacozzolino costitemsinmelanomapatientsbyclinicalcharacteristicsandtimefromdiagnosis AT claudiacozzolino costitemsinmelanomapatientsbyclinicalcharacteristicsandtimefromdiagnosis AT annazanovello costitemsinmelanomapatientsbyclinicalcharacteristicsandtimefromdiagnosis AT annazanovello costitemsinmelanomapatientsbyclinicalcharacteristicsandtimefromdiagnosis AT ruggerogeppini costitemsinmelanomapatientsbyclinicalcharacteristicsandtimefromdiagnosis AT andreamiatton costitemsinmelanomapatientsbyclinicalcharacteristicsandtimefromdiagnosis AT manuelzorzi costitemsinmelanomapatientsbyclinicalcharacteristicsandtimefromdiagnosis AT mariagiovannamanfredi costitemsinmelanomapatientsbyclinicalcharacteristicsandtimefromdiagnosis AT emanuelabovo costitemsinmelanomapatientsbyclinicalcharacteristicsandtimefromdiagnosis AT paolodelfiore costitemsinmelanomapatientsbyclinicalcharacteristicsandtimefromdiagnosis AT saveriatropea costitemsinmelanomapatientsbyclinicalcharacteristicsandtimefromdiagnosis AT luigidallolmo costitemsinmelanomapatientsbyclinicalcharacteristicsandtimefromdiagnosis AT luigidallolmo costitemsinmelanomapatientsbyclinicalcharacteristicsandtimefromdiagnosis AT carloriccardorossi costitemsinmelanomapatientsbyclinicalcharacteristicsandtimefromdiagnosis AT simonemocellin costitemsinmelanomapatientsbyclinicalcharacteristicsandtimefromdiagnosis AT simonemocellin costitemsinmelanomapatientsbyclinicalcharacteristicsandtimefromdiagnosis AT marcorastrelli costitemsinmelanomapatientsbyclinicalcharacteristicsandtimefromdiagnosis AT marcorastrelli costitemsinmelanomapatientsbyclinicalcharacteristicsandtimefromdiagnosis AT massimorugge costitemsinmelanomapatientsbyclinicalcharacteristicsandtimefromdiagnosis AT massimorugge costitemsinmelanomapatientsbyclinicalcharacteristicsandtimefromdiagnosis |